Background: Survival after cardiac surgery of patients formerly affected by lymphoma has not been well defined.

Methods: Forty-five consecutive patients having prior Hodgkin's (HL patients, n=26) or non-Hodgkin's lymphoma (non-HL patients, n=19) underwent on-pump cardiac surgery at the authors' institution (2001-2016). Ischaemic, valvular, and ischaemic plus valvular heart disease were present in 14, 13, and 18 patients, respectively. Concomitant aortic disease was treated in three cases. The expected operative risk was calculated by the European System for Cardiac Operative Risk Evaluation (EuroSCORE) II. The 10-year survival was estimated by the Kaplan-Meier method and the Charlson Comorbidity Index (CCI). The Cox proportional-hazards regression was used to evaluate the effect of some risk factors on survival.

Results: With respect to non-HL patients, HL patients were younger (mean age, 52.5 vs. 64.7 years, p=0.0017) and underwent cardiac surgery later after lymphoma occurrence (median gap, 21.5 vs. 9.6 years, p=0.0079). No other intergroup differences as baseline characteristics, risk profiles (median EuroSCORE II, 2.3% vs. 3%, p=0.78), and in-hospital mortality (7.7% vs. 10.5%, p=0.99) were found. Older age, severe left ventricular dysfunction, and HL history were predictors of cardiac or cerebrovascular death (p<0.1). The 10-year, crude (40.4%) and adjusted (39.1%) nonparametric estimates of survival were lower than the expected survival by CCI (77.5%, p<0.0001). The 10-year nonparametric estimate of freedom from malignancy was 66.3%.

Conclusions: Immediate and long-term survival after on-pump cardiac surgery of patients formerly affected by lymphoma were worse than expected, according to universally used predictive scoring systems. There was an increased risk of malignant tumour.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hlc.2017.11.008DOI Listing

Publication Analysis

Top Keywords

cardiac surgery
16
on-pump cardiac
8
patients
8
surgery patients
8
patients lymphoma
8
non-hl patients
8
ischaemic valvular
8
operative risk
8
cardiac
6
early late
4

Similar Publications

Where does the tether break in vertebral body tethering cases? Clinical insights from revision cases after tether breakage.

Spine Deform

January 2025

Department of Spine Surgery, Eifelklinik St Brigida, St. Brigida Eifelklinik, Kammerbruchst. 8, 52152, Simmerath, Germany.

Purpose: To evaluate the sites where the tether breaks in vertebral body tethering (VBT) cases.

Methods: Intraoperative evaluation of broken tethers in patients who had anterior revision.

Inclusion Criteria: anterior revision of VBT cases with explantation of the full implant and photo documentation.

View Article and Find Full Text PDF

This case report presents an atypical transverse cervical artery with its detailed anatomy, morphogenesis, and association with the high arch-shaped subclavian artery. The atypical arteries, related arteries, and adjacent cervical and brachial plexuses were macroscopically examined in a 98-year-old Japanese female cadaver donated to The Nippon Dental University for medical education and research. The atypical deep branch of the transverse cervical artery originated from the internal thoracic artery and passed through between the C5 and C6 roots, in close contact with the C5 and C6 junction, to reach the dorsal side of the brachial plexus.

View Article and Find Full Text PDF

Relationship between intraoperative blood pressure variability and postoperative acute kidney injury in pediatric cardiac surgery.

Pediatr Nephrol

January 2025

Department of Anesthesiology, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610000, Sichuan, China.

Background: Cardiac surgery-associated acute kidney injury (CSA-AKI) is a notably common complication in pediatrics, with an incidence rate ranging from 15 to 64%. This rate is significantly higher than that observed in adults. Currently, there is a lack of substantial evidence regarding the association between intraoperative blood pressure variability (BPV) during cardiac surgery with cardiopulmonary bypass (CPB) and the development of AKI in pediatric patients.

View Article and Find Full Text PDF

Targeted editing of CCL5 with CRISPR-Cas9 nanoparticles enhances breast cancer immunotherapy.

Apoptosis

January 2025

Department of Breast Cancer Surgery, Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology, No. 519 Beijing East Road, Nanchang, Jiangxi, 330029, China.

Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide. Immunotherapy, a promising therapeutic approach, often faces challenges due to the immunosuppressive tumor microenvironment. This study explores the innovative use of CRISPR-Cas9 technology in conjunction with FCPCV nanoparticles to target and edit the C-C Motif Chemokine Ligand 5 (CCL5) gene, aiming to improve the efficacy of breast cancer immunotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!